Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$5.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Thomas H. Jensen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Beta
- 0.57
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -8.78
Financials
Revenue
$5.0KNet Income
$-6.20MEBITDA
$-5.16MFree Cash Flow
$-2.88MEPS (diluted)
$-0.39Shares Outstanding (diluted)
15.94M+531152.2%Operating Expenses
$5.51MCash & Debt
$14.10MReturn of Capital
$0.00Revenue by Segment (annual)
$320.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $320.0K | $-11.23M | $-0.78 |
| 2024 | $0.00 | $-24.52M | $-15.79 |
| 2023 | $0.00 | $-11.90M | $-6031.31 |
| 2022 | $0.00 | $-16.06M | $-2.21 |
| 2021 | $0.00 | $-26.65M | $-4.19 |
| 2020 | $0.00 | $-6.60M | $-1698639.00 |
| 2019 | $120.0K | $-14.31M | $-189613.00 |
| 2018 | $1.46M | $-2.29M | $0.00 |
| 2017 | $1.46M | $-4.90M | $0.00 |
| 2016 | $143.3K | $-3.68M | $0.00 |
| 2015 | $362.3K | $-1.15M | $0.00 |
| 2014 | $10.0K | $-68.7K | $-0.06 |
| 2013 | $0.00 | $-81.2K | $0.00 |
Valuation
ALLRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·4d ago·Neutral
Allarity Therapeutics Granted U.S. Patent for Stenoparib's Clinical Dosing Regimen, with Protection Into 2045 Patent with 36 allowed claims covering twice-daily treatment in ovarian cancer and other solid tumors
View source ↗ - Newsglobenewswire.com·9d ago·Neutral
Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance - Ended third quarter with $24.1 million in cash and restricted cash - Expects positive fourth quarter earnings between $0.01 and $0.04 per share
View source ↗ - Newszacks.com·44d ago·Neutral
Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock Now After losing some value lately, a hammer chart pattern has been formed for Allarity Therapeutics, Inc. (ALLR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research - Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity's research capabilities to enable external partnerships
View source ↗ - Newsglobenewswire.com·72d ago·Neutral
…al Allocation for Filing of SPAC Registration Statement TARPON SPRINGS, Fla., September 11, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor using its proprietary DRP® technology, announced that Allarity Acquisition Corp., a newly formed special purpose acquisition company (SPAC), has publicly filed a Registration Statement on Form S-…
View source ↗ - Newsglobenewswire.com·100d ago·Positive
…P ® testing to accelerate and support U.S. clinical trials TARPON SPRINGS, Fla., AUGUST 14, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the second quarter ended June 30, 2026.
View source ↗
Earnings
Mon, Mar 29(in 4 months)
Consensus estimate $-0.21 per share
Typical surprise +16.7% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Nov 13$-0.39 vs $-0.21miss
- Fri, Aug 14$-0.21 vs $-0.25beat
- Fri, May 15$-0.17 vs $-0.22beat
- Tue, Mar 31$-0.19 vs $-0.22beat
- Fri, Nov 14$-0.19 vs $-0.23beat
- Fri, Aug 15$-0.15 vs $-0.21beat
Estimates and results for ALLR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ALLR officers and directors.
No open-market trades in the recent filings. All 60 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
60 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ALLR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
